GL1X · GenesisL1 explorer

MolNFT v1 · #55391 · protein

X-ray structure of mycobacterium tuberculosis dodecin

2YIZ: “X-ray structure of mycobacterium tuberculosis dodecin”. X-ray diffraction, 3 ligands (COA, FMN, CL), 3 pockets (best druggability 0.46). MolNFT v1 #55391 on GenesisL1: 3D structure, binding sites and pockets in GL1X.

PDB
2YIZ
Type
protein
Length
272 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Dodecin
UniProt
Q8VK10
Ligands
COA, FMN, CL
Pockets
3 · best druggability 0.46

Structure

x-ray diffraction · 1 distinct chain · 22% helix, 56% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, B, C, DDodecinprotein6822% helix, 56% strandQ8VK10

Ligands and binding sites

  • COA · Coenzyme A · ligand · 4 copies · chains A, B, C, D
  • FMN · Flavin mononucleotide · ligand · 4 copies · chains A, C, D, B
  • CL · Chloride ion · ion · 2 copies · chains B, A, C
  • GOL · Glycerol · additive · 5 copies · chains A, C, B, D
  • TRS · 2-amino-2-hydroxymethyl-propane-1,3-diol · additive · chains C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 0 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
11560.460.7621FMN
2970.450.7912GOL
3510.320.7716COA

Interfaces

5 interfaces between chains.

  • A–D · 558 Ų buried · 6 hydrogen bonds · protein-protein
  • B–D · 558 Ų buried · 6 hydrogen bonds · protein-protein
  • A–B · 557 Ų buried · 6 hydrogen bonds · protein-protein
  • A–C · 539 Ų buried · 10 hydrogen bonds · protein-protein
  • C–D · 43 Ų buried · 0 hydrogen bonds · protein-protein

Compared structures

  • 2YIZ · X-ray structure of Mycobacterium tuberculosis Dodecin · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.